Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
SPECIFICATIONS Specifications GLP-1 Detection and quantification of GLP-1 activity 0.32 nM - 0.0128 nM (GLP-1 (7-36) amide, Orforgliopron) 1.6 nM - 0.064 nM (Semaglutide) 1.6 nM - 0.1 nM (Retatrutide) 8 nM - 0.32 nM (Tirzepatide) Complete DMEM (see TDS) Verified using Plasmotest Each lot is functionally tested and validated
Patients on tirzepatide lost an average of 20.2% of their body weight over 72 weeks Patients on semaglutide lost an average of 13.7% of their body weight over the same period 47% more tirzepatide patients achieved 25% or greater body weight loss compared to semaglutide Tirzepatide also produced greater reductions in waist circumference across all dose comparisons A 2024 meta-analysis published in JAMA Internal Medicine analyzing real-world data from over 140,000 patients confirmed the same pattern: tirzepatide produced an average of 4.23 kg more weight loss than semaglutide across all doses and durations studied
It is characterized by recurrent episodes of consuming large quantities of food in a discrete period, accompanied by a sense of loss of control and marked distress
Rekha Kumar, an endocrinologist and obesity specialist at Weill Cornell Medicine and New York Presbyterian
US$ 23.07
US$ 29.61
US$ 21.31
US$ 21.41
US$ 25.04
US$ 26.24
